From Prediction to Decision Making: PBPK and QSP as Regulatory-Grade NAMs Publication From Prediction to Decision Making: PBPK and QSP as Regulatory-Grade NAMs New CPT review by Certara's Karen Rowland Yeo & Piet van der Graaf shows how…Danielle Pillsbury2026年9月23日
Tailwinds for MIDD: EMA, FDA, and a Converging Regulatory Landscape Live Events Tailwinds for MIDD: EMA, FDA, and a Converging Regulatory Landscape 2026年10月29日 - 11:00 PM – 2:00 PMChara Litou2026年9月9日
Application of PBPK Modeling Tools in Biopharmaceutics On-Demand Webinar 薬物吸収モデルの応用例 Learn how PBPK modeling supports formulation design and how virtual bioequivalence may offer an alternative…Noriko Okudaira, PhD2026年8月26日
Beyond Trial and Error: Model-Informed Formulation Development in Practice On-Demand Webinar Beyond Trial and Error: Model-Informed Formulation Development in Practice Learn how model-informed formulation development and PBPK modeling can guide formulation strategy, bioequivalence, and biowaiver…Siri Kalyan Chirumamilla2026年8月24日
Tailwinds for MIDD: What to Know About the Changing Regulatory Landscape Live Events Tailwinds for MIDD: What to Know About the Changing Regulatory Landscape 2026年9月30日 - 11:30 PM – 2:00 PMCertara2026年8月12日
Assessing Cross-Version Simcyp Simulator Prediction Performance Using a Bioequivalence Framework to Support EMA Qualification Poster Assessing Cross-Version Simcyp Simulator Prediction Performance Using a Bioequivalence Framework to Support EMA Qualification See how Simcyp Simulator V20–V24 DDI predictions were shown equivalent to the EMA-qualified V19 using…Certara2026年7月24日
When to conduct hepatic impairment studies and when modeling may be enough Blog When to conduct hepatic impairment studies and when modeling may be enough How to decide if a hepatic impairment study is required, choose the right study design,…Zoe Barter2026年7月13日
Integrated mechanistic modeling approaches in oncology drug development On-Demand Webinar Integrated mechanistic modeling approaches in oncology drug development Learn how integrated QSP and PBPK modeling supports dose justification, patient stratification, and regulatory decisions…Certara2026年7月8日
PBPK Modeling in Lieu of Clinical Endpoint Bioequivalence Study for Generic Tazarotene Cream 0.05% Poster PBPK Modeling in Lieu of Clinical Endpoint Bioequivalence Study for Generic Tazarotene Cream 0.05% Learn how Simcyp PBPK modeling established bioequivalence and supported FDA approval of a generic productCertara2026年7月1日
The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors On-Demand Webinar The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors Learn how PBPK and QSP modeling support faster drug development by enabling smarter dose selection,…Certara2026年7月1日